Skip to content

The impact of intra-cardiac shunt on the pharmacodynamics and pharmacokinetics of cis-atracurium in adult patients with congenital heart diseases

The impact of intra-cardiac shunt on the pharmacodynamics and pharmacokinetics of cis-atracurium in adult patients with congenital heart diseases

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR-ROC-15006836
Enrollment
Unknown
Registered
2015-07-30
Start date
2015-04-30
Completion date
Unknown
Last updated
2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Adult Congenital Heart Diseases with Intra-Cardiac Shunt

Interventions

Control group:No intervention, Only monitoring
VSD group:No intervention, Only monitoring
ASD group:No intervention, Only monitoring
TOF group:No intervention, Only monitoring
SV group:No intervention, Only monitoring

Sponsors

Guangdong General Hospital, Guangdong Academy of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 55 Years

Inclusion criteria

Inclusion criteria: Forty cases of adult patients with congenital heart diseases (with 10 cases of ventricular septal defect, atrial septal defect, tetralogy of Fallot or single ventricle in each group) to receive elective corrective surgeries. All genders, age 18~55 years old, BMI 20~24 kg/m2, ASA grade below III. All the patients are diagnosed as adult congenital heart diseases with intra-cardiac shunt by ultrasonography with normal lung, liver and kidney function. All the patients have no known hematological or neuromuscular conduction diseases, no medications affecting neuromuscular conduction taken before the surgeries and no histories of muscle relaxants allergy.

Exclusion criteria

Exclusion criteria: Patients with lung, liver or kidney dysfunction. Patients with neuromuscular conduction dysfunction. Patients taking medications affecting muscle relaxants before surgeries. Patients with known histories of anesthetic allergies. Patients with severe valvular stenosis or regurgitation. Patients or the family members refusing to participate the research.

Design outcomes

Primary

MeasureTime frame
Plasma concentration of cis-atracurium;Onset time of cis-atracurium;

Countries

China

Contacts

Public ContactSheng Wang
shengwang_gz@163.com+86 13560182353

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026